SIRPA Specific Neutra™ Antibody Products
Product listSignal regulatory protein α (SIRPA), also known as SHPS1 or SIRPα, is a regulatory membrane glycoprotein that is ubiquitously expressed in tissues, particularly high in the brain. As a single-pass type I membrane protein, SIRPA is the receptor of CD47 that transduces the "don't eat me" signal. SIRPA is associated with many diseases such as glioblastoma, and pancreatic cancer.
Its Gene ID: 140885, UniProtKB ID: P78324, and OMIM ID: 602461.
Blockade of the CD47-SIRPα Pathway
The blockade of the CD47-SIRPα signaling system has high therapeutic potential to promote tumor elimination in various cancers.
- Enhances macrophage-mediated antibody-dependent cellular phagocytosis (ADCP) of cancer cells with SIRPα/CD47 blocking Abs and tumor antigen-specific therapeutic Abs binding to FcγR.
- Induces and promotes macrophage-mediated ADCP through a dual mechanism of SIRPα-blocking Abs binding to specific tumor cells and macrophages.
- Promotes cytotoxic T cells and NK cells, which contributes to ADCP effects in cancer therapy.
- Inhibits tumor growth and metastasis.
Fig.1 Blockade of CD47-SIRPα interaction suppresses tumor growth and metastasis.1
Treatment Strategy about CD47-SIRPα
Anti-tumor strategies based on the blockade of the CD47-SIRPα axis are being developed for a broad spectrum of cancers. The strategies listed below could promote cytotoxic T-cell activity and generate a synergistic antitumor effect.
- Bispecific Abs targeting tumor-specific antigens and blocking the CD47-SIRPα axis.
- Immune checkpoint inhibitors such as Abs against PD1/PDL1 and CD47/SIRPα.
- Combination therapy with surgery, chemotherapy, or radiotherapy.
Fig.2 Combined blockade treatment strategy of CD47-SIRPα and PD1-PDL1 interactions.1
Clinical Significance of SIRPA
Table 1 provides a list of biological agents, including anti-CD47/SIRPα Abs and recombinant fusion proteins that block the human CD47-SIRPα interaction. These drug candidates are currently under investigation for several malignancies listed below.
Tab. 1 Drugs targeting CD47-SIRPα interaction.2
Blocking CD47-SIRPα interaction is potentially a novel approach for cancer immunotherapy. Creative Biolabs offers anti-SIRPA antibodies for immunoassays. These antibodies with good specificity and affinity were performed quality control with commercial SIRPA antigens.
Fig.3 Human SIRPA protein was detected in ELISA using anti-SIRPA antibody (V3S-0622-YC5366).
Fig.4 Human SIRPA protein was serially diluted and probed with anti-SIRPA antibody (V3S-0622-YC5366) in Dot blot.
References
- Murata, Yoji.; et al. "CD 47-signal regulatory protein α signaling system and its application to cancer immunotherapy." Cancer Science 109.8 (2018): 2349-2357.
- Catalán, Rodrigo.; et al. "CD47-SIRPα axis as a biomarker and therapeutic target in cancer: current perspectives and future challenges in nonsmall cell lung cancer." Journal of Immunology Research 2020 (2020): 1-8.
